Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
CHICAGO, April 11, 2016 -- The Female Health Company (NASDAQ:FHCO) (FHC or the Company) today announced the creation of a new abstract entitled "FC2 Dual Protection, Non-Hormonal, Latex Free Female Condom" and authored by Brooke Faught, MSN, WHNP-BC; Irwin Goldstein, MD; Mark Martens, MD; Kelli Rodriguez; and Lisa Levin.
On February 25, 2016, the abstract was presented at the International Society for the Study of Women’s Sexual Health (ISSWSH) 2016 Annual Meeting in Charleston, South Carolina. The study surveyed women (ages 25-64) regarding their use of the FC2 Female Condom. Results of the survey indicated a very high percentage (82%) would recommend FC2 to others, and the same percentage (82%) stated positive ease of use. The abstract will also be presented at the Academy of Women’s Health’s “Women's Health 2016: The 24th Annual Congress” taking place from April 14 to April 17, 2016 in Washington, DC.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, the Zika virus, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to [email protected].
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123
